Future drugs in the treatment of glaucomatous neuropathy: Introduction to neuroprotection;Perspectives dans le traitement medical de la neuropathie glaucomateuse: Bases de la neuroprotection

Journal Francais d'Ophtalmologie

Volumn 22, Issue 1, 1999, Pages 122-134

  Detry Morel, M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BETAXOLOL; BRIMONIDINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DORZOLAMIDE; ENDOTHELIN RECEPTOR ANTAGONIST; FLUNARIZINE; FLUPIRTINE; GLUTAMATE RECEPTOR ANTAGONIST; GROWTH FACTOR; HEAT SHOCK PROTEIN; LATANOPROST; MEMANTINE; NEUROPROTECTIVE AGENT; NIFEDIPINE; NIMODIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; PENTOXIFYLLINE; PHENYTOIN; THIOPENTAL; VERAPAMIL;

AQUEOUS HUMOR FLOW; DRUG EFFICACY; GLAUCOMA; HUMAN; NERVE REGENERATION; NEUROPROTECTION; OPTIC NERVE DISEASE; REVIEW; TRABECULAR MESHWORK; FORECASTING;

FORECASTING; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES;

EID: 0033071703     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Quigley HA. The relationship of intraocular pressure and glaucomatous optic neuropathy. In «Pharmacology of Glaucoma. St. Drance, EM Van Buskirk, AH Neufeld (ed)». Williams and Wilkins 1992;16:265-71.
2. Wilson MR. The «myth of 21». Journal of Glaucoma 1997;6:65-77.
3. Jampel HD. Target pressure in glaucoma therapy. Journal of Glaucoma 1997;6:133-8.
4. Caprioli J. Avenues toward neuroprotection of the optic nerve in glaucoma. In: «GLAUCOMA: Decision making in Therapy. M.G. Bucci (Ed)». Springer-Verlag Italia, Milano 1996: 323-7.
5. Neufeld AH. Protection of the Optic nerve in Glaucoma. In: «Pharmacology of Glaucoma. St. Drance EM, Van Buskirk AH (ed)». Neufeld. Williams and Wilkins 1992;19:292-300.
6. Drance SM. Glaucoma: a look beyond intraocular pressure. Am J Ophthalmol 1997;123:817-9.
7. James B. Bloodflow in the pathogenesis of Glaucoma. Current Opinion in Ophthalmol 1993;11:65-72.
8. Carenini BB, Broglatti B, Carenini AB, Sibour G, Demarie G. Ischaemia and Glaucoma. New Trends in Ophthalmol 1993;8:75-80.
9. Flammer J, Gasser P, Prunte C, Ke Yao. The probable involvement of other factors than intraocular pressure in the pathogenesis of Glaucoma. In: «Pharmacology of Glaucoma. St. Drance EM., Van Buskirk AH (ed)». Neufeld Williams and Wilkins, 1992;17:273-81.
10. O'Donoghue EP. Blood Fow: a target for ocular therapy in Glaucoma ? In: «Glaucoma: Decision making in Therapy. MG Bucci (Ed)». Springer-Verlag Italia, Milano 1996:299-306.
11. Flammer J. Endothelin in the pathogenesis of Glaucoma. Vascular Risk Facors and Neuroprotection in Glaucoma-Update 1996. St. Drance (ed). Kugler Publications by, Amsterdam-New York 1997:97-103.
12. Haefliger I O. Endothelium-dependent vasoactive factors in the ophthalmic circulation. Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996. S. Drance (ed). Kugler Publications by, Amsterdam-New York 1997:15-28.
13. Osborne NN. Neuroprotection to the retina: relevance in Glaucoma.Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996, edited by ST. Drance. Kugler Publications by Amsterdam-New York 1997;139-55.
14. Osborne NN, Laesen A, Barnett NL. Influence of excitatory Amino Acids and Ischemia on rat retinal choline acetyltransferase-containing cells. Invest Ophthalmol Vis Sci, 1995;36:1692-700.
15. Tasindi E, Talu H. Differential effect of betaxolol and timolol on the progression of glaucomatous visual field loss. Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996, edited by ST. Drance. Kugler Publications by Amsterdam-New York, 1997:227-34.
16. Saver JL, Demer JL, Starkman S. Editorial: Emerging therapies for acute ischemic stroke. Am J Ophthalmol 1997;124:384-93.
17. Chew SJ, Ritch R. Neuroprotection: the next breakthrough in glaucoma ? Proceedings of the third annual optic nerve rescue and restoration think tank. J Glaucoma, 1997;6:263-6.
18. Becker B, Stamper RL, Podos SM. Effect of diphenylhydantoin on Glaucomatous field loss: a preliminary report. Tr Am Acad Ophth and Otol 1972;76:412-22.
19. 2+-antagonist on visual field in low-tension glaucoma. Graefe's Arch Clin Exp Ophthalmol 1989;227:408-12.
20. Pillunat LE, Kuba GB, Harris A. Ocular vasospasm and calcium channel blockers in Glaucoma. In: «Glaucoma: Decision making in Therapy. MG Bucci (Ed)». Springer-Verlag Italia, Milano 1996:189-95.
21. 2+ entry blockers on ocular vessels. Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996, ed. by ST Drance. Kugler Publications by Amsterdam-New York, 1997:123-34.
22. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated Glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol, 1996;114:299-305.
23. Vorwerk CK, Lipton SA, Zurakowski., Hyman BT, Sbel BA, Dreyer EB. Chronic low-dose Glutamate is toxic to retinal ganglion cells. Toxicity blocked by Memantine. Invest Ophthalmol Vis Sci 1996;37:1618-24.
24. Gupta LY, Marmor MF. Mannitol, Dextromethorphan, and catalase minimize ishemic damage to retinal pigment epithelium and retina. Arch Ophthalmol 1993;111:384-8.
25. Yoon YH, Marmor MF. Dextromethorphan protects retina against ischemic injury in vivo. Arch Ophthalmol 1989;107:409-11.
26. Cao W, Drumheller A, Casanova C, Lafond G, Brunette JR, Jolicœur FB. Effects of dextromethorphan on ischemia induced electroretinogram changes in rabbit. Curr Eye Res, 1994;13:97-102.
27. Osborne NN, Schwarz M, Pergande G. Protection of rabbit retina from ishemic injury by Flupirtine. Invest Ophthalmol Vis Sci 1996;37:274-80.
28. Takahashi K, Lam TT, Edward DP, Buch ER, Tso MO. Protective effects of Flunarizine on ischemic injury in the rat retina. Arch Ophthalmol 1992;110:862-70.
29. Pulido JS, Fukuda M, Howe CA, Puro DG. Barbiturates protect retinal cells from hypoxia in cell culture. Arch Ophthalmol 1989;107:1809-12.
30. Meduri RA, Bozza D, Grossi G, Preda P, Sprovieri C, Scorolli L, Leopardi G. Antioxydant drugs and Glaucoma. In: «GLAUCOMA: Decision making in Therapy. MG Bucci (Ed)». Springer-Verlag, Italia, Milano 1996:313-7.
31. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49 (suppl. 1):S26-S33.
32. Aguayo AJ, Vidal-Sanz M, Villegas-Perrez MP, Keirstead SA, Rasminsky M, Bray GM. Axonal regrowth and connectivity from neurons in the adult rat retina. In: «Retinal signal systems, degenerations and transplants. Agardh E, Ehinger B (eds)». Elsevier Science Publishing, New York 1986:257-70.
33. Varela HJ, Hernandez MR. Astrocyte responses in human optic nerve head with primary open-angle glaucoma. J Glaucoma 1997;6:303-13.
34. Harris A, Evans D, Martin B. Individual responsiveness to ocular vasodilatation. Vascular Risk Factors and Neuroprotection in Glaucoma. Update 1996, edited by St. Drance. Kugler Publications by, Amsterdam-New York 1997:105-13.
35. Sponsel WE, Shipman D. Effects of Blood gases on ocular perfusion. Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996. Edited by St. Drance. 1997 Kugler Publications by, Amsterdam-New York 1997:65-71.
36. Dettmann ES, Flammer J, Heafliger IO. Magnesium and vascular tone modulation. Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996. Edited by St. Drance. Kugler Publications by, Amsterdam/New York 1997:79-86.
37. Hamard P, Hamard H, Dufaux J. Hémorhéologie de la neuropathie glaucomateuse. Bull Soc Belg Ophtalmol 1992;244:17-25.
38. Tielsch JM. Vascular risk factors for primary open-angle Glaucoma. Oral communication presented at the International Symposium on Neuroprotection and Vascular Risk Factors in Glaucoma. Nassau (Bahamas), 6-8 mars 1998.
39. Aim A. Etiological and pharmacological aspects on blood flow and Glaucoma. Vascular Risk Factors and Neuroprotection in Glaucoma-Update 1996, edited by St. Drance. Kugler Publications by, Amsterdam-New York 1997:167-72.
40. Epstein DL. Medications used in chronic glaucoma therapy. Potential new drugs. In: «Chandler and Grant's Glaucoma, fourth Edition. DL Epstein (ed)». Williams and Wilkins 1996;ch 16:173-5.
41. Liang LL, Epstein DL, De Kater AW, Shahsafaei A, Erickson-Lamy KA. Ethacrinic acid increased facility of outflow in the human eye in vitro. Arch Ophthalmol 1992;110:106-9.
42. Melamed S, Kotas-Neumann R, Barak A, Epstein DL. The effect of intracamerally injected ethacrinic acid on intraocular pressure in patients with Glaucoma. Am J Ophthalmol 1992;113:508-12.
43. Wang RF, Podos SM, Serie JB, Lee PY, Neufels AH, Deschenes R. Effects of topical ethacrinic acid ointment vs timolol on intraocular pressure in glaucomatous monkey eyes. Arch Ophthalmol 1994;112:390-4.
44. Kaufman PL. New thoughts on outflow. Oral presention at the Subspeciality day AAO 1997. Under Pressure: Glaucoma 1997, San Francisco, 25 oct 1997.
45. Orgül S, Meyer P, Cioffi GA. Physiology of blood flow regulation and mechanisms involved in optic nerve perfusion. J Glaucoma 1995;4:427-43.